Charles Peloquin

About

Charles Peloquin, Pharm.D., is the Jack C. Massey Endowed Professor and Past Associate Chair of the Department of Pharmacotherapy and Translational Research at the University of Florida College of Pharmacy. Prior to his tenure at UF, he completed a hospital pharmacy residency at Duke University Medical Center, where he also served on the clinical staff. He further completed a fellowship in Infectious Diseases and Pharmacokinetics at the Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y. For 20 years, Dr. Peloquin was the Director of the Infectious Disease Pharmacokinetics Laboratory at National Jewish Health in Denver, Colorado, where he now serves as a Professor of Pharmacy and Medicine. His laboratory is part of the UF Emerging Pathogens Institute and functions as a national reference center for determining serum concentrations of antimycobacterial, antifungal, anti-HIV, and antibacterial drugs, including beta-lactams and linezolid. His research primarily focuses on therapeutic drug monitoring and clinical trials for patients with advanced mycobacterial diseases. Dr. Peloquin has served as a consultant to the FDA, CDC, and WHO, and has contributed to national guidelines on tuberculosis treatment and the treatment of opportunistic infections in patients living with AIDS. His notable accomplishments include receiving the Roger Jelliffe Individualized Therapy Award in 2024 and the American College of Clinical Pharmacology Lifetime Achievement Award…

Research topics

• Medicine
• Microbiology
• Biology
• Internal medicine
• Pharmacology
• Pathology
• Immunology
• Intensive care medicine
• Chemistry
• Nuclear medicine

Selected publications

• The Treatment of Tuberculosis

  Clinical Pharmacology & Therapeutics · 2021 · 127 citations

  1st authorCorresponding

  Tuberculosis (TB) remains a leading cause of infectious death worldwide, and poverty is a major driver. Clinically, TB presents as "latent" TB and active TB disease, and the treatment for each is different. TB drugs can display "early bactericidal activity (EBA)" and / or "sterilizing activity" (clearing persisters). Isoniazid is excellent at the former, and rifampin is excellent at the latter. Pyrazinamide and ethambutol complete the first-line regimen for drug-susceptible TB, each playing a sp…

  DOI

• Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions

  Nature Medicine · 2020 · 127 citations

  DOI

• Beta-lactam target attainment and associated outcomes in patients with bloodstream infections

  International Journal of Antimicrobial Agents · 2023 · 47 citations

  Senior authorCorresponding
  PublisherDOI

• Using Machine Learning To Define the Impact of Beta-Lactam Early and Cumulative Target Attainment on Outcomes in Intensive Care Unit Patients with Hospital-Acquired and Ventilator-Associated Pneumonia

  Antimicrobial Agents and Chemotherapy · 2022 · 37 citations

  Senior authorCorresponding

  ) were calculated for time frames of 0 to 24 h, 0 to 10 days, and day 0 to end of therapy. Regression analyses and machine learning were performed to evaluate the impact of PK/PD on therapy outcomes. A total of 735 patients and 840 HAP/VAP episodes (47% HAP) were included. The mean age was 56 years, and the mean weight was 80 kg. Sequential organ failure assessment (SOFA), hemodialysis, age, and weight were significantly associated with the clinical outcomes and kept in the final model. In the f…

  DOI

• Use of therapeutic drug monitoring to characterize cefepime‐related neurotoxicity

  Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2022 · 27 citations

  STUDY OBJECTIVES: Data evaluating cefepime thresholds associated with neurotoxicity remain limited. The objectives of this study were to evaluate the incidence of cefepime-related neurotoxicity (CRN) in patients with plasma cefepime concentrations, assess the relationship between cefepime exposure and CRN, investigate clinical factors associated with CRN, and describe electroencephalogram (EEG) abnormalities in CRN. DESIGN: This was a retrospective study of adult inpatients admitted between 2016…

  DOI

Recent grants

• Administrative Core

  NIH · $24.0M · 2016–2022

• NIH Grant R01AI037845

  NIH · $1.0M · 2000

Frequent coauthors

• Andrew Vernon

  Centers for Disease Control and Prevention

  177 shared

• William J. Burman

  Public Health Institute

  160 shared

• Marc Weiner

  153 shared

• Awal Khan

  Centers for Disease Control and Prevention

  130 shared

• Stephen E. Weis

  Nuffield Health

  128 shared

• Debra Benator

  Washington DC VA Medical Center

  88 shared

• Charles L. Daley

  University of Colorado Anschutz Medical Campus

  86 shared

• Zhen Zhao

  72 shared

Labs

• Infectious Disease Pharmacokinetics LabPI

Education

• Other, Hospital Pharmacy

  Duke University Medical Center

• Other, Infectious Diseases and Pharmacokinetics

  Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital

• Other, Infectious Disease Pharmacokinetics

  Infectious Disease Pharmacokinetics Laboratory (IDPL)

Awards & honors

• Roger Jelliffe Individualized Therapy Award 2024
• American College of Clinical Pharmacology Lifetime Achieveme…

Similar researchers at University of Florida

• Yan Gongh-65
• Joseph Collinsh-61
• Jatinder Lambah-60